133 related articles for article (PubMed ID: 6801812)
1. Fibrinogen New Orleans: hereditary dysfibrinogenemia with an A alpha chain abnormality.
Andes WA; Chavin SI; Beltran G; Stuckey WJ
Thromb Res; 1982 Jan 1-15; 25(1-2):41-50. PubMed ID: 6801812
[TBL] [Abstract][Full Text] [Related]
2. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A.
Matsuda M; Saeki E; Kasamatsu A; Nakamikawa C; Manabe S; Samejima Y
Thromb Res; 1985 Feb; 37(3):379-90. PubMed ID: 3992527
[TBL] [Abstract][Full Text] [Related]
3. Fibrinogen Sapporo: dysfibrinogenemia characterized by the replacement of A alpha arginine-16 by histidine resulting in the delayed release of fibrinopeptide A by thrombin.
Asakura S; Terukina S; Yamazumi K; Matsuda M; Murayama H; Higuchi A; Musashi M; Sakurada K; Miyazaki T
Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1094-104. PubMed ID: 2588959
[TBL] [Abstract][Full Text] [Related]
4. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
Lane DA; Cuddigan B; VanRoss M; Kakkar VV
Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
[TBL] [Abstract][Full Text] [Related]
5. Fibrinogen Seattle releases half the normal amount of fibrinopeptide B.
Branson HE; Schmer G; Theodor I; Pirkle H
Acta Haematol; 1983; 70(4):257-63. PubMed ID: 6414212
[TBL] [Abstract][Full Text] [Related]
6. Fibrinogen Bondy: a new case of dysfibrinogenemia. Isolation of the abnormal fibrinogen molecules.
Jandrot-Perrus M; Aurousseau MH; Rabiet MJ; Josso F
Thromb Res; 1982 Sep; 27(6):659-70. PubMed ID: 6217586
[TBL] [Abstract][Full Text] [Related]
7. A new congenital abnormal fibrinogen Ise characterized by the replacement of B beta glycine-15 by cysteine.
Yoshida N; Wada H; Morita K; Hirata H; Matsuda M; Yamazumi K; Asakura S; Shirakawa S
Blood; 1991 May; 77(9):1958-63. PubMed ID: 2018836
[TBL] [Abstract][Full Text] [Related]
8. Fibrinogen Barcelona I. Congenital dysfibrinogenemia characterized by defective release of fibrinopeptide A and fibrinogen degradation products.
Vila V; Regañón E; Aznar J; Navarro G; Salas M
Thromb Res; 1987 Mar; 45(5):437-49. PubMed ID: 2954261
[TBL] [Abstract][Full Text] [Related]
9. [Fibrinogen Bern III: a further case of hereditary fibrinogen variants with substitution A alpha 16 Arg----Cys].
Furlan M; Leupin L; Biasiutti FD; Lämmle B
Schweiz Med Wochenschr; 1991 Jul; 121(29):1068-71. PubMed ID: 1891701
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution.
Borrell M; Vila L; Solá J; Coll I; Fontcuberta J
Haemostasis; 1990; 20(1):1-7. PubMed ID: 2323678
[TBL] [Abstract][Full Text] [Related]
11. Fibrinogen Aarhus--a new case of dysfibrinogenemia.
Hessel B; Stenbjerg S; Dyr J; Kudryk B; Therkildsen L; Blombäck B
Thromb Res; 1986 Apr; 42(1):21-37. PubMed ID: 2939591
[TBL] [Abstract][Full Text] [Related]
12. Fibrinogen kaiserslautern III: a new case of congenital dysfibrinogenemia with aalpha 16 arg-->cys substitution.
Loreth RM; Meyer M; Albert FW
Haemostasis; 2001; 31(1):12-7. PubMed ID: 11408744
[TBL] [Abstract][Full Text] [Related]
13. Fibrinogen Milano. VI: A heterozygous dysfibrinogenemia (A alpha 16 Arg----His) with bleeding tendency.
Bögli C; Cofrancesco E; Cortellaro M; Della Volpe A; Hofer A; Furlan M; Zanussi C
Eur J Haematol; 1990 Jul; 45(1):26-30. PubMed ID: 2379562
[TBL] [Abstract][Full Text] [Related]
14. Fibrinogen Seattle II: defective release of fibrinopeptide A in a slow clotting fibrinogen.
Schreiber WE; Schmer G
Thromb Res; 1985 Jan; 37(1):45-52. PubMed ID: 3983901
[TBL] [Abstract][Full Text] [Related]
15. Hereditary dysfibrinogenemia characterized by slow fibrinopeptide release and competitive inhibition of thrombin.
Laugen RH; Bithell TC
Acta Haematol; 1984; 71(3):150-7. PubMed ID: 6424379
[TBL] [Abstract][Full Text] [Related]
16. Fibrinogen Bergamo I (A alpha 16Arg----Cys): susceptibility towards thrombin following aminoethylation, methylation or carboxamidomethylation of cysteine residues.
Reber P; Furlan M; Beck EA; Finazzi G; Buelli M; Barbui T
Thromb Haemost; 1985 Aug; 54(2):390-3. PubMed ID: 4082078
[TBL] [Abstract][Full Text] [Related]
17. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
[TBL] [Abstract][Full Text] [Related]
18. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (A alpha 16 Arg----His) containing heterodimeric molecules.
Siebenlist KR; Prchal JT; Mosesson MW
Blood; 1988 Mar; 71(3):613-8. PubMed ID: 3345340
[TBL] [Abstract][Full Text] [Related]
19. Fibrinogen Houston: a dysfibrinogen exhibiting defective fibrin monomer aggregation and alpha-chain cross-linkages.
Weinger RS; Rudy C; Moake JL; Conlon CL; Cimo PL
Am J Hematol; 1980; 9(3):237-48. PubMed ID: 6165239
[TBL] [Abstract][Full Text] [Related]
20. Fibrinogen Logroño. A new case of congenital dysfibrinogenemia.
Rocha E; Lasierra J; Narvaiza MJ; Vilades E; Palacios E; Fernandez J
Ric Clin Lab; 1984; 14(4):663-72. PubMed ID: 6522973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
